Immunization

It is unclear why the vaccines were less effective in women, but researchers note that the findings can be important when determining immune therapy outcomes in patients with melanoma.

Calder’s 3D Vaxlock technology attained 11 times more effective immune response, compared to typical comparator.

The adjuvanted RSVPreF3 vaccine could prevent nearly 3 million symptomatic RSV-ARI cases among US older adults over 3 years’ time, according to study results.

Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.

Positive data were presented at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Disease in Cape Town, South Africa.

Merck will also conduct clinical trials in both males and females to evaluate the efficacy of a single dose of their current human papillomavirus vaccine compared with the approved 3-dose regimen.

Legal issues surfaced once again with the COVID-19 pandemic

The pneumococcal vaccine was most likely associated with a higher risk of immunological events for those who were immunocompromised

Investigators also found that those with community-acquired, radiology-confirmed pneumonia with lower respiratory tract infections had worse outcomes.

Investigators determined that the vaccination reduced the prevalence of vaccine serotypes with an effectiveness of 89.6% based on the study results.

Investing in community relationships and health literacy are key steps pharmacists can take to improve equity.

Despite the growth in vaccine and antibody development for combatting RSV, lower income countries may not reap the benefits.

The findings suggest that 6 months after vaccination with ARCT-154, individuals had a longer immune response.

Investigators found high incidences of non-susceptibility with penicillin and increasing resistance to macrolides for pneumococcal diseases.

The 23-valent pneumococcal polysaccharide vaccine was most likely associated with a higher risk of immunological events for those who were immunocompromised, but the events were low.

Addressing complacency, confidence, and convenience are all crucial to increasing vaccine uptake.

Older adults without a Part D plan face costs ranging from $180 to $295 per shot.

Infection-induced immunity with 2-dose vaccination still offered protection against the circulating variant.

The schedule includes RSV vaccination, along with updated versions of the COVID-19 vaccine.

Despite Travis Kelce’s recent commercial with Pfizer, data show celebrity endorsements do not convince listeners to receive immunizations

Individuals with PCV20-serotype disease were generally younger compared to those who had PCV13 serotype community-acquired pneumonia.

According to the study investigators, findings indicat that pneumococcal vaccination in older adults and other interventions should be considered for reducing the disease burden.

Stress may have more of an effect on migraines than COVID-19 infection or vaccination.

If vaccination coverage was increased by 100%, outpatient care could be reduced by 81.2%, hospitalizations by 91.7%, and deaths by 91.3%.

Investigators optimized the assay during development and qualification to be used in the clinical setting for pneumococcal conjugate vaccines.

The study highlights the ongoing need for health care providers to recommend respiratory illness vaccinations to increase protection among nursing home residents during the peak season of infection.

However, comprehensive policy and payment structures are needed to ensure care sustainability.

The study results also determined that those who were previously vaccinated against smallpox had a 2.7 times higher immune response than those who were not previously vaccinated.

The SHARE model from the CDC involves personalizing recommendations for patients and their needs, addressing any concerns they may have, and explaining the risks of remaining unvaccinated.

The study authors note that the findings could be significant in future HIV vaccine design and development, as well as new approaches to HIV immunotherapy.